DK2753355T3 - Onkolytisk herpes simplex virus og terapeutiske anvendelser deraf - Google Patents

Onkolytisk herpes simplex virus og terapeutiske anvendelser deraf Download PDF

Info

Publication number
DK2753355T3
DK2753355T3 DK12830105.8T DK12830105T DK2753355T3 DK 2753355 T3 DK2753355 T3 DK 2753355T3 DK 12830105 T DK12830105 T DK 12830105T DK 2753355 T3 DK2753355 T3 DK 2753355T3
Authority
DK
Denmark
Prior art keywords
hsv
gene
variant
promoter
tumor
Prior art date
Application number
DK12830105.8T
Other languages
English (en)
Inventor
Ian J Mohr
Matthew C Mulvey
Original Assignee
Univ New York
Benevir Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York, Benevir Biopharm Inc filed Critical Univ New York
Application granted granted Critical
Publication of DK2753355T3 publication Critical patent/DK2753355T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Claims (33)

1. Variant af herpes simplex virus (HSV) omfattende: a. funktionelt inaktive ICP34.5 kodende gener; b. US11 kodende gen operabelt forbundet med en immediate early (IE) promoter; c. intakt endogent US11 kodende gen; d. intakt endogent Usl2 kodende gen; og e. gen der koder for et heterologt TAP-inhibitor-polypeptid, hvor det heterologe TAP-inhibitor-polypeptid er et herpes virus-UL49.5 TAP-inhibitor-polypeptid, et CMV US6-polypeptid, eller et BNLF2a-polypeptid.
2. HSV-varianten ifølge krav 1, hvor HSV-varianten er afledt fra HSV-1.
3. HSV-varianten ifølge enten krav 1 eller 2, hvor HSV-varianten er afledt fra vildtype HSV-1, HSV-1 stamme F, HSV-1 stamme 17, HSV-1 KOS, HSV-1 stamme Patton, eller en HSV-1 klinisk stamme.
4. HSV-varianten ifølge et hvilket som helst af kravene 1-3, hvor HSV-varianten er mindst 70% identisk med HSV-1 eller HSV-2.
5. HSV-varianten ifølge et hvilket som helst af kravene 1-4, hvor HSV-varianten er afledt fra SEQ ID NO: 1.
6. HSV-varianten ifølge et hvilket som helst af kravene 1-5, hvor UL49.5 TAP-inhibitor-polypeptidet er afledt fra kvæg-herpes virus, pseudorabies virus, heste herpes virus 1, heste herpes virus 4, bubaline herpesvirus 1, hjorte herpes virus 1, eller katte herpesvirus 1.
7. HSV-varianten ifølge krav 6, hvor UL49.5 TAP-inhibitor-polypeptidet er afledt fra kvæg-herpesvirus.
8. HSV-varianten ifølge et hvilket som helst af kravene 1-7, hvor ICP34.5 generne er gjort funktionelt inaktive ved deletion, substitution, eller insertion.
9. HSV-varianten ifølge et hvilket som helst af kravene 1-7, hvor mindst ét af ICP34.5 generne er gjort funktionelt inaktive ved indsætningen af en ekspressionskassette.
10. HSV-varianten ifølge et hvilket som helst af kravene 1-7, hvor mindst ét af ICP34.5 generne er gjort funktionelt inaktive uden indsætning afen ekspressionskassette.
11. HSV-varianten ifølge et hvilket som helst af kravene 1-10, hvor det intakte endogene US11 kodende gen er udtrykt fra den endogene sene promoter lokaliseret inde i Usl2-genet.
12. HSV-varianten ifølge et hvilket som helst af kravene 1-11, hvor IE-promoteren er valgt fra en CMV, EFla, aO, a4, a22, a47, og en a27 IE promoter.
13. HSV-varianten ifølge et hvilket som helst af kravene 1-12, hvor HSV-varianten yderligere omfatter et heterologt gen der koder fra et polypeptid valgt fra granulocyt makrofag kolonistimulerende faktor (GM-CSF), tumornekrosefaktor (TNF)-alfa, CD40 ligand (CD40L), IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-1 1, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, G-CSF, IFN-a, IFN-γ, IL-20 (MDA-7), B7-1 (CD80) og B7-2 (CD86).
14. HSV-varianten ifølge krav 13, hvor det heterologe gen koder for GM-CSF.
15. HSV-varianten ifølge krav 13, hvor det heterologe gen koder for IL-12.
16. HSV-varianten ifølge et hvilket som helst af kravene 13-15, hvor det heterologe gen eller genet der koder for det heterologe TAP-inhibitor-polypeptid er operabelt forbundet med en eukaryot eller viruspromoter.
17. HSV-varianten ifølge krav 16, hvor promoteren er en CMV promoter, en MMLV LTR promoter, en RSV promoter, eller en EFla promoter.
18. HSV-varianten ifølge et hvilket som helst af kravene 13-15, hvor det heterologe gen eller genet der koder for det heterologe TAP-inhibitor-polypeptid er operabelt forbundet med en inducerbar promoter.
19. HSV-varianten ifølge et hvilket som helst af kravene 1-18 omfattende: a. funktionelt inaktive ICP34.5 kodende gener; b. US11 kodende gen operabelt forbundet med en immediate early (IE) promoter; c. gen der koder for et UL49.5 TAP-inhibitor-polypeptid; d. intakt endogent US11 kodende gen; e. intakt endogent Usl2 kodende gen; og f. gen der koder for GM-CSF.
20. HSV-varianten ifølge krav 19, hvor genet der koder for UL49.5 TAP-inhibitor-polypeptidet er afledt fra kvæg herpesvirus.
21. HSV-varianten ifølge enten krav 19 eller 20, hvor genet der koder for UL49.5 TAP-inhibitor-polypeptidet er operabelt forbundet med en eukaryot eller viruspromoter.
22. HSV-varianten ifølge et hvilket som helst af kravene 19-21, hvor genet der koder for GM-CSF er operabelt forbundet med en eukaryot eller viruspromoter.
23. HSV-varianten ifølge enten krav 21 eller 22, hvor promoteren er en CMV promoter, en MMLV LTR promoter, en RSV promoter, eller en EFla promoter.
24. HSV-varianten ifølge et hvilket som helst af kravene 1-23, hvor genet der koder for det heterologe TAP-inhibitor-polypeptid er indsat nedstrøms for det US11 kodende gen operabelt forbundet med immediate early (IE) promoteren.
25. HSV-varianten ifølge et hvilket som helst af kravene 1-24, hvor genet der koder for det heterologe TAP-inhibitor-polypeptid er indsat i den samme orientering som det US11 kodende gen.
26. HSV-varianten ifølge et hvilket som helst af kravene 13-25, hvor det heterologe gen er indsat nedstrøms for det US11 kodende gen.
27. HSV-varianten ifølge et hvilket som helst af kravene 13-26, hvor det heterologe gen er indsat i den samme orientering som det US11 kodende gen.
28. HSV-varianten ifølge et hvilket som helst af kravene 14 eller 19-23, hvor genet der koder for det heterologe TAP-inhibitor-polypeptid og det heterologe gen der koder for humant GM-CSF er operabelt forbundet med den samme promoter.
29. HSV-varianten ifølge krav 1 der har en genomsekvens som vist i SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, eller SEQ ID NO: 30.
30. HSV-varianten ifølge krav 1, der har et intakt endogent US12 kodende gen og et intakt endogent US11 kodende gen, mangler funktionelt ICP34.5 kodende gener, hvor hvert ICP34.5 kodende gen er erstattet med en polynukleotidkassette omfattende en nukleinsyresekvens som vist i en af SEQ ID NO: 21, SEQ ID NO: 22: SEQ ID NO: 23, SEQ ID NO: 24 og SEQ ID NO: 25.
31. Farmaceutisk formulering omfattende HSV-varianten ifølge et hvilket som helst af kravene 1-30 og en farmaceutisk acceptabel bærer.
32. HSV-varianten ifølge et hvilket som helst af kravene 1-30 eller den farmaceutiske sammensætning ifølge krav 31, til anvendelse i en fremgangsmåde til behandling cancer hos en patient, hvilken fremgangsmåde omfatter at administrere til patienten HSV-varianten eller den farmaceutiske sammensætning.
33. HSV-varianten eller den farmaceutiske formulering til anvendelse ifølge krav 32, hvor canceren er valgt fra gruppen bestående af bryst, hjerte, livmoderhals, colon, hoved og hals, lever, nyrer, lunge, ikke-småcellet lunge, melanom, mesotheliom, æggestok, sarkom, mave, livmoder og Medulloblastom, Hodgkin's sygdom, Non-Hodgkin's lymphom, multipel myelom, neuroblastom, æggeledercancer, rhabdomyosarkom, primær thrombocytose, primær macroglobulinæmi, primære hjernetumorer, malignt pankreatisk insulanom, malignt carcinoid, urinblærecancer, premaligne hudlæsioner, testikelcancer, lymphomer, skjoldbruskkirtelcancer, neuroblastom, øsofagealcancer, urogenitalkanalcancer, malignt hypercalcæmi, endometriecancer, adrenal cortical cancer, neoplasmer af den endokrine og exokrine bugspytkirtel, og prostatacancer.
DK12830105.8T 2011-09-08 2012-09-07 Onkolytisk herpes simplex virus og terapeutiske anvendelser deraf DK2753355T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161532335P 2011-09-08 2011-09-08
PCT/US2012/054206 WO2013036795A2 (en) 2011-09-08 2012-09-07 Oncolytic herpes simplex virus and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
DK2753355T3 true DK2753355T3 (da) 2019-01-28

Family

ID=47832785

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12830105.8T DK2753355T3 (da) 2011-09-08 2012-09-07 Onkolytisk herpes simplex virus og terapeutiske anvendelser deraf

Country Status (14)

Country Link
US (5) US9623059B2 (da)
EP (1) EP2753355B1 (da)
CA (1) CA2846372C (da)
CY (1) CY1121591T1 (da)
DK (1) DK2753355T3 (da)
ES (1) ES2704632T3 (da)
HR (1) HRP20182194T1 (da)
HU (1) HUE041799T2 (da)
LT (1) LT2753355T (da)
PL (1) PL2753355T3 (da)
PT (1) PT2753355T (da)
RS (1) RS58146B1 (da)
SI (1) SI2753355T1 (da)
WO (1) WO2013036795A2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
WO2016141320A2 (en) * 2015-03-05 2016-09-09 Northwestern University Non-neuroinvasive viruses and uses thereof
SG11201805835WA (en) * 2016-01-08 2018-08-30 Replimune Ltd Modified oncolytic virus
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
CN110461346A (zh) 2017-03-15 2019-11-15 美国安进公司 溶瘤病毒单独或与检查点抑制剂组合用于治疗癌症的用途
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3661954B1 (en) 2017-08-03 2022-02-09 Amgen Inc. Interleukin-21 muteins and methods of treatment
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
WO2019075233A1 (en) * 2017-10-12 2019-04-18 Massachusetts Eye And Ear Infirmary METHODS FOR RAPID DETECTION AND IDENTIFICATION OF PATHOGENIC OLEITY AGENTS
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
CR20210319A (es) 2018-01-12 2021-07-27 Amgen Inc ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
TW202039835A (zh) 2018-12-27 2020-11-01 美商安進公司 凍乾病毒配製物
BR112021017551A2 (pt) 2019-03-05 2021-11-09 Amgen Inc Uso de vírus oncolíticos para o tratamento de câncer
US20200283796A1 (en) 2019-03-05 2020-09-10 Massachusetts Institute Of Technology Dna launched rna replicon system (drep) and uses thereof
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN111850126B (zh) * 2020-08-06 2022-11-01 北京市神经外科研究所 溶瘤病毒在葡萄膜黑色素瘤治疗上的应用、治疗效果的标记物及其检测试剂
BR112023023032A2 (pt) 2021-05-05 2024-02-15 Janssen Biotech Inc Redirecionamento universal do hsv oncolítico

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2629818B1 (fr) 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
US5071743A (en) 1989-10-27 1991-12-10 Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada Process for conducting site-directed mutagenesis
FR2662440B1 (fr) 1990-05-22 1992-07-31 Rhone Poulenc Sante Procede de preparation stereoselective de derives de la phenylisoserine.
FR2662441B1 (fr) 1990-05-22 1992-10-23 Rhone Poulenc Sante Procede de preparation enantioselective de derives de la phenylisoserine.
WO1993001282A1 (en) 1991-07-01 1993-01-21 Berlex Laboratories, Inc. Novel mutagenesis methods and compositions
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
EP0906420A1 (en) 1996-06-07 1999-04-07 Massachusetts Institute Of Technology Programmed sequential mutagenesis
US5780270A (en) 1996-07-17 1998-07-14 Promega Corporation Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
EP1190040B1 (en) * 1999-06-08 2007-08-22 UAB Research Foundation Herpes simplex virus expressing interleukin-12 gene and and its use for treating cancer
IL131212A0 (en) * 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
ES2233600T5 (es) * 2000-01-21 2009-06-22 Biovex Limited Cepas de virus del herpes.
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
WO2002076216A1 (en) 2001-03-27 2002-10-03 Medigene, Inc. Viral vectors and their use in therapeutic methods
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2006002394A2 (en) * 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2008069663A1 (en) * 2006-12-07 2008-06-12 Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp

Also Published As

Publication number Publication date
CA2846372A1 (en) 2013-03-14
US20180369301A1 (en) 2018-12-27
US9623059B2 (en) 2017-04-18
PL2753355T3 (pl) 2019-04-30
US11147846B2 (en) 2021-10-19
ES2704632T3 (es) 2019-03-19
WO2013036795A3 (en) 2014-05-15
US10456432B2 (en) 2019-10-29
EP2753355A4 (en) 2015-05-06
US20150110822A1 (en) 2015-04-23
CY1121591T1 (el) 2020-07-31
CA2846372C (en) 2021-01-12
SI2753355T1 (sl) 2019-02-28
US20200113956A1 (en) 2020-04-16
PT2753355T (pt) 2019-02-01
EP2753355B1 (en) 2018-10-24
WO2013036795A2 (en) 2013-03-14
US20220031779A1 (en) 2022-02-03
RS58146B1 (sr) 2019-02-28
HUE041799T2 (hu) 2019-05-28
US10105404B2 (en) 2018-10-23
EP2753355A2 (en) 2014-07-16
HRP20182194T1 (hr) 2019-02-22
LT2753355T (lt) 2019-01-25
US20170216381A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
DK2753355T3 (da) Onkolytisk herpes simplex virus og terapeutiske anvendelser deraf
AU2019204982B2 (en) Recombinant HCMV and RhCMV Vectors and Uses Thereof
KR102006527B1 (ko) 전립선-연관 항원의 발현을 위한 벡터
KR20150014505A (ko) 아과 e 원숭이 아데노바이러스 a1302, a1320, a1331 및 a1337 및 이것들의 사용
KR20200074132A (ko) 리소좀 장애를 위한 유전자 요법
AU2015289560B2 (en) Human cytomegalovirus comprising exogenous antigens
DK2623594T3 (da) Antistof mod human prostaglandin-E2-receptor EP4
AU2022200903B2 (en) Engineered Cascade components and Cascade complexes
KR20220038362A (ko) 재조합 ad35 벡터 및 관련 유전자 요법 개선
KR20220098384A (ko) 폼페병 및 리소좀 장애를 치료하기 위한 간-특이적 프로모터를 포함하는 치료적 아데노-관련 바이러스
AU2021232778A1 (en) Oncolytic HSV1 vector and methods of use
JP2023145678A (ja) エプスタインバールウイルス抗原構築物
KR20200083510A (ko) 아데노바이러스 및 이의 용도
WO1998020016A1 (en) Novel coding sequences from herpes simplex virus type-2
KR20230031929A (ko) 고릴라 아데노바이러스 핵산 서열 및 아미노산 서열, 이들을 함유하는 벡터, 및 이의 용도
KR20210053923A (ko) 항종양 면역 반응을 자극하는 키메라 종양 용해성 허피스바이러스
CN116940589A (zh) 重组sars-cov-2疫苗
CN111065408A (zh) 免疫原性组合物
CN114761030A (zh) 具有诱导的抗肿瘤免疫的溶瘤病毒疗法
KR102039631B1 (ko) U38, u40 및 u41의 일부 서열을 포함하는 재조합 단순 헤르페스 바이러스 셔틀 벡터의 제조 방법
CN116323955A (zh) 通过crispr/cas介导的体内末端解析拯救重组腺病毒
RU2800085C2 (ru) Химерный онколитический вирус герпеса, стимулирующий противоопухолевый иммунный ответ
RU2774631C1 (ru) Сконструированные компоненты cascade и комплексы cascade
KR102039634B1 (ko) U38, u340 및 u41의 일부 서열을 포함하는 재조합 단순 헤르페스 바이러스 셔틀 벡터
KR102039632B1 (ko) Icp 6 결실 및 gm-csf 유전자를 포함하는 재조합 단순 헤르페스 바이러스 셔틀 벡터의 제조 방법